NASDAQ · GANX
Gain Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for GANX: Nov 11, 2026
Gain Therapeutics, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.13. The reported EPS for the same quarter last year was $-0.15.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.13 | $-0.12 | $-0.13 | 3 |
| Dec 2026 | $-0.13 | $-0.11 | $-0.15 | 3 |
| Mar 2027 | $-0.13 | $-0.12 | $-0.13 | 2 |
| Jun 2027 | $-0.13 | $-0.12 | $-0.13 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · NASDAQ.com · BNK Invest- Fintel · Oct 29, 2:48 AM EDTGain Therapeutics, Inc. Appoints Jeanette Weidner as Vice President, Finance, Effective October 28, 2026Gain Therapeutics, Inc. appointed Jeanette Weidner as its Vice President, Finance, with an effective date of October 28, 2026. In this role, Ms. Weidner will also serve as the Company’s principal financial officer and principal accounting officer. Ms. Weidner, 44, has 18 ye
- RTTNews · Aug 17, 2:30 AM EDTGain Posts Narrower Loss In Q2; Phase 1b Data For Rexaceract Due In Q4 2026(RTTNews) – Gain Therapeutics, Inc. (GANX), a clinical-stage biotech company, reported a narrower second quarter loss due to lower operating expenses, higher interest income and a foreign exchange gain.
- RTTNews · Jul 17, 6:15 AM EDTGain Updates Parkinson's Pipeline, Promotes Executives; Cash Runway Into Q2 2027(RTTNews) – Gain Therapeutics, Inc. (GANX) President and CEO, Gene Mack on Thursday provided investors with an update on the company's progress of its clinical pipeline, leadership initiatives, and cash position.
- NASDAQ.com · Jun 29, 7:59 PM EDTAfter Hours Most Active for Jun 29, 2026 : CAG, NVDA, GANX, INN, AAPL, ARI, ANNX, RKT, CSCO, CMG, ACN, HTZThe NASDAQ 100 After Hours Indicator is down -47.33 to 30,229.02. The total After hours volume is currently 289,974,742 shares traded.The following are the most active stocks for the after hours session: ConAgra Brands, Inc. (CAG) is -0.02 at $13.96, with 76,796,445 shares trade
- RTTNews · Apr 24, 2:50 PM EDTGain To Present New Parkinson's Disease Data On GT-02287 At International GBA1 Meeting; Stock Up(RTTNews) – Gain Therapeutics, Inc. (GANX) will deliver an oral presentation next month highlighting new updates on its lead Parkinson's disease candidate, GT-02287.
- BNK Invest · Mar 18, 11:59 AM EDTWednesday Sector Laggards: Precious Metals, Biotechnology StocksIn trading on Wednesday, precious metals shares were relative laggards, down on the day by about 5.6%. Helping drag down the group were shares of I-80 Gold, off about 13.6% and shares of Novagold Resources down about 9.8% on the day. Also lagging the market Wednesday are biote
- Zacks · Dec 22, 12:00 PM ESTGain Therapeutics (GANX) Upgraded to Buy: Here's WhyGain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Fintel · Dec 20, 7:24 PM ESTGain Therapeutics (GANX) Price Target Increased by 11.76% to 7.75The average one-year price target for Gain Therapeutics (NasdaqGM:GANX) has been revised to $7.75 / share. This is an increase of 11.76% from the prior estimate of $6.94 dated December 3, 2025. The price target is an average of many targets provided by analyst
- Fintel · Dec 19, 7:07 PM ESTHC Wainwright & Co. Reiterates Gain Therapeutics (GANX) Buy RecommendationFintel reports that on December 19, 2025, HC Wainwright & Co. reiterated coverage of Gain Therapeutics (NasdaqGM:GANX) with a Buy recommendation. Analyst Price Forecast Suggests 141.25% Upside
- Zacks · Dec 18, 9:40 AM ESTIs Enhabit, Inc. (EHAB) Stock Outpacing Its Medical Peers This Year?Here is how Enhabit (EHAB) and Gain Therapeutics, Inc. (GANX) have performed compared to their sector so far this year.
- Zacks · Dec 8, 12:00 PM ESTHere's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to BuyDoes Gain Therapeutics, Inc. (GANX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks · Nov 17, 12:00 PM ESTGain Therapeutics (GANX) Upgraded to Buy: Here's What You Should KnowGain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Gain Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.